AstraZeneca Plc (STO: AZN) reported on Tuesday that as of 31 December 2017, the issued share capital of the company with voting rights was 1,266,221,605 ordinary shares of USD0.25.
Also, no shares are held in treasury. Therefore, the total number of voting rights in AstraZeneca Plc was 1,266,221,605.
According to the company this figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca Plc under the UK Financial Conduct Authority's Disclosure and Transparency Rules.
AstraZeneca is a science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in the three therapy areas of Oncology, Cardiovascular & Metabolic Diseases and Respiratory. It is also selectively active in the areas of autoimmunity, neuroscience and infection.
GE HealthCare expands Vivid cardiovascular ultrasound portfolio with three new systems
Daiichi Sankyo data highlight real-world impact of bempedoic acid on cardiovascular risk
Revier Therapeutics closes EUR6m seed financing and launches operations
Tempus announces receipt of FDA clearance for AI pulmonary hypertension detection product
European Commission grants orphan designation for Lundbeck's asedebart
Hanmi Pharm enters exclusive licensing deal with Genentech for obesity therapy HM17321
PTC to acquire BLA-stage ST-920 Fabry disease programme
Olio Labs reveals study demonstrating AI-driven in vivo platform can predict clinical trial outcomes
Mezzion Pharma Co reports positive results from new in vivo study of udenafil
Incyte's Opzelura approved in European Union for moderate atopic dermatitis